PharmaLegacy will be exhibiting at the 2024 meeting of the Association for Research in Vision & Ophthalmology May 5–9 in Seattle. Visit us at booth #4703 and discuss predicting outcomes for potential treatments with our latest ophthalmology models. You can register here for ARVO 2024 We hope to see you in Seattle! The post PHARMALEGACY TO EXHIBIT AT ARVO MAY 5-9 2024 IN SEATTLE, WASHINGTON appeared first on PharmaLegacy | Preclinical Pharmacology CRO ..read more

PharmaLegacy will be attending Bio-Europe Spring, March 18-20 in Barcelona Spain. Let’s connect there to discuss the latest trends and challenges in the pharma industry. You can register here for Bio-Europe Spring, and email michael.zhang@pharmalegacy.com to schedule a meeting. We hope to see you in Barcelona! The post PHARMALEGACY ATTENDING BIO-EUROPE SPRING MARCH 18-20, 2024 IN SPAIN appeared first on PharmaLegacy | Preclinical Pharmacology CRO ..read more

PharmaLegacy will be exhibiting at the 2024  Society Of Toxicology’s 63rd annual meeting and ToxExpo March 11– 13 in Salt Lake City. Visit us at booth #940 and let’s discuss how our fast, cost-effective toxicology services can bolster your studies. To register at ToxExpo 2024, visit https://www.toxicology.org/events/am/AM2024/registration.asp#:~:text=Exhibitor%20Registration,3115). We hope to see you in Salt Lake City! The post PharmaLegacy to exhibit at ToxExpo March 11-13 2024 in Utah appeared first on PharmaLegacy | Preclinical Pharmacology CRO ..read more

Recently, The Lancet published the world’s first clinical trial study on gene therapy for hereditary deafness. This study has proved the safety and demonstrated the great potential of gene therapy for the treatment of hereditary deafness, which has attracted extensive attention from medical community. The deafness gene therapy drug RRG-003 (AAV1-hOTOF), used in this study was jointly developed by Eye & ENT Hospital of Fudan University, Harvard Medical School and Shanghai Refreshgene Therapeutics Co., Ltd. This study reported the safety and efficacy of gene therapy with an adeno-associated ..read more

  PharmaLegacy will be exhibiting at the 2023 meeting of the American Association for Cancer Research April 14 – 18 in  Florida. Visit us at booth #71 and discuss predicting outcomes for potential treatments with our latest oncology and immuno-oncology in vitro and in vivo models. To register for AACR 2022, visit https://www.annualconference2023.com/aacr/?gclid=Cj0KCQjwwtWgBhDhARIsAEMcxeAk0-cT_qLX_fVmdTHKvgmbeSE-n_qFBu9Gpl7yB2bjd1tnvdZU4N8aAgFHEALw_wcB  We hope to see you in Florida! The post PHARMALEGACY TO EXHIBIT AT AACR APRIL 14-19, 2023 IN FLORIDA appeared fi ..read more

PharmaLegacy has reaffirmed that all of its non-human primates (NHPs) are farm-raised for research use. Supplier providence and detailed animal information can be provided to all clients upon request. The US Department of Justice is investigating primates being illegally smuggled from Cambodia for research purposes. This has led to concerns about a shortage of primates for biomedical research. The PharmaLegacy team has re-reviewed the records for all of our NHP and none have been imported from Cambodia. If you have used our models in the past or are planning a study for the future, you can be ..read more

PharmaLegacy will be exhibiting at the 2022 meeting of the American Association for Cancer Research April 10 – 13 in New . Visit us at booth #728 and discuss predicting outcomes for potential treatments with our latest oncology and immuno-oncology in vitro and in vivo models. To register for AACR 2022, visit https://www.aacr.org/meeting/aacr-annual-meeting-2022/registration/ We hope to see you in New Orleans! The post PharmaLegacy to Exhibit at AACR 2022 April 10 – 13 in New Orleans appeared first on PharmaLegacy | Preclinical Pharmacology CRO ..read more